Previous 10 |
Acumen’s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Initiated ACU-001, a multi-center, randomized, double-blind, placebo-contro...
We have witnessed a record last week, with 19 launched IPOs and almost $10 billion raised. That is the most companies in one week since 2004. Even more, the NYSE floor which has been rather quiet in the past year came back to life. SPACs have been favored for a good part of 2020 and the beg...
Last week turned out to be the busiest IPO week since 2004. Nearly $10 billion was raised in 19 public offerings. DiDi Global (NYSE: DIDI), a Chinese ride-hailing app with 15 million drivers across 4,000 towns and cities, led the way by raising $4.4 billion at a $70.4 billion market cap. Se...
In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global. Cybersecurity platform SentinelOne (S) upsized and priced above the upwardly revised range to raise $1.2 billion at a $10.6 billion market cap....
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer’s disease (AD),&...
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), to...